X

Trial Profile

Real World Effectiveness of Natalizumab Extended Interval Dosing in Relapsing-Remitting Multiple Sclerosis in a French Cohort

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 15 Feb 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Natalizumab (Primary)
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms RELEVANT

Most Recent Events

10 Feb 2023 Primary endpoint (Annualized Relapse Ratio) has been met according to Results published in the Neurology and Therapy.
10 Feb 2023 Results assessing Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort published in the Neurology and Therapy
28 Jun 2022 Results (N=303) presented at the 8th Congress of the European Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com